Targovax ASA: Invitation to Second Quarter and First Half Year 2018 Results Presentation Thursday 23 August
OSLO, Norway, Aug 15, 2018 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors, will announce its second quarter and first half year 2018 results on Thursday, 23 August 2018. A presentation by Targovax's management to investors, analysts and the press will take place in Oslo at 10:00 CET.
The results report and the presentation will be available at www.targovax.com in the Investors section from 07:00 CET.
Presentation
The presentation will take place at 10:00 CET at:
Hotel Continental Stortingsgaten 24/26 0117 Oslo
The presentation will also be webcast live and can be accessed through www.targovax.com.
For further information, please contact: Renate Birkeli, Investor Relations Phone: +47-922-61-624 Email: [email protected]
Media and IR enquires: Andreas Tinglum - Corporate Communications (Norway) Phone: +47-9300-1773 Email: [email protected]
GERDAU S.A. hereby announces that the Form 20-F related to the fiscal year ended December 31, 2023 was filed with the U.S. Securities and Exchange Commission (SEC) at http://sec.gov and with the Securities and Exchange Commission of Brazil (CVM) at...
Americas Gold and Silver Corporation ("Americas" or the "Company"), a growing North American precious metals producer, reports consolidated financial and operational results for the year ended December 31, 2023.
This earnings release should be...
Westhaven Gold Corp. is pleased to announce that it has closed the final tranche of the non-brokered private placement announced on February 20, 2024. Westhaven has issued a total of 7,926,182 common shares that qualify as "flow-through shares" of...
Greenberg Traurig Senior Vice President, Shareholder, and Chief Diversity, Equity & Inclusion (DEI) Officer Nikki Lewis Simon was a panelist during the National Association...
Revenue
Revenue for the year was $238.5, down $1.4 from sales of $239.9 in 2022. The Company's sales were flat when compared to 2022 and 2021 included a fifteen month period due to the accounting change from September 30 to December 31.
Twelve-month...